Yeh-Chuin Poh, PhD, is VP and Head of Technical Operations at Tolerance Bio, advancing thymus-based therapies to restore immune tolerance. He has led CMC and process development efforts across multiple INDs, including at Beam Therapeutics and Semma Therapeutics (acquired by Vertex), and co-founded Absolute Nano (acquired by United Science).